Q-omics provides the consensus-scored KRT18P14 profile across patient tissues and cancer cell-line models. KRT18P14 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT18P14 is differentially expressed in 8, with the highest sampling consensus in STAD. Additionally, KRT18P14 RNA expression shows 7,436 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, STAD, and ESCA as cancer lineages where KRT18P14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT18P14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT18P14 survival associations across molecular data types. KRT18P14 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT18P14 RNA expression–survival associations across cancer types. High KRT18P14 expression shows unfavorable associations in LUAD, PAAD and MESO, but favorable associations in KIRC, LAML and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT18P14 RNA expression.
This table summarizes KRT18P14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRT18P14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT18P14 shows lower tumor expression in PAAD and higher tumor expression in STAD, BRCA, LUAD, COAD and KIRC. The STAD box plot shows higher KRT18P14 RNA expression in tumor versus normal tissue (log2 FC = +0.139, t-test p = .002).
This table shows molecular features associated with KRT18P14 in patient tissues and cancer cell lines. In patient samples, KRT18P14 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
